Oryzon today announced the presentation of the trial in progress (TIP) FRIDA poster entitled Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myelo...
Read moreOryzon Genomics, S.A. a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first ...
Read moreOryzon Genomics announced today that its management will give an update on corporate progress at several international events on May-June
Read moreOryzon Genomics S.A., announced today positive outcome from its planned, prespecified interim analysis of its Phase 2b trial, PORTICO, with vafidemstat for borderline personality disorder (BPD). These...
Read moreOryzon Genomics announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia (A...
Read moreOryzon Genomics, S.A, announced today the nomination of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development candidate for the treatment of certain neurological dise...
Read moreOryzon Genomics S.A. announced that it will host a virtual panel discussion discussing the unmet medical needs in specific central nervous system (CNS) and oncology diseases, such as Borderline Person...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreIt has been announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).
Read moreLa aportación de Oryzon se destinará a distribuir la vacuna neumocócica en Mozambique y Etiopía para prevenir la neumonía, la mayor causa de mortalidad infantil por enfermedad infecciosa a escala...
Read moreOryzon Genomics, S.A., de acuerdo al ranquin publicado por la Unión Europea, es la empresa española con mayor intensidad de inversión en I+D por empleado y que ocupa el numero 20 en el listado de 2...
Read more